




# PHARMACEUTICAL 2019

Viracta Therapeutics Inc.  
Rank 315 of 363





RealRate

# PHARMACEUTICAL 2019

Viracta Therapeutics Inc.  
Rank 315 of 363



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 14% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -148%, being 185% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	15,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,323
Liabilities, Non-Current	8.0
Other Assets	113
Other Compr. Net Income	7.0
Other Expenses	1,154
Other Liabilities	0
Other Net Income	249
Other Revenues	237
Property and Equipment	11
Research and Development	14,615
Selling, General and Administrative Expense	11,332

Output Variable	Value in 1000 USD
Assets	15,324
Liabilities	11,331
Expenses	27,101
Revenues	237
Stockholders Equity	3,993
Net Income	-26,615
Comprehensive Net Income	-26,612
Economic Capital Ratio	-148%